Form 4 for VTGN Vistagen Therapeutics, Inc.
Accepted 2024-01-03 00:00:00 ET · period of report 2023-12-29 · accession 0001415889-24-000344 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-03 | 2023-12-29 | VTGN | Singh Shawn | CEO, Dir | A - Grant | $1.72 | +167 | 5,633 | +3% | +$287.24 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-29 | A | A | 167 | $1.72 | 5,633 | D | — | — | (F1) Shares purchased pursuant to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan. |